Hanem M. Awad

Hanem M. Awad is a distinguished researcher at Egypt's National Research Centre since 1997, with significant academic affiliations at Taif University, Mining Studies and Research Unit (Saudi Arabia), Wageningen University & Research, and TNO (Netherlands). Her institutional collaborations span multiple continents, reflecting her international research impact.

Her research centers on synthesizing novel biomedical compounds for cancer treatment, with specialized expertise in nanotechnology (particularly selenium nanoparticles), phytochemistry, molecular modeling, and heterocyclic chemistry. She designs compounds targeting specific oncological pathways like VEGFR-2 inhibition to disrupt tumor growth and angiogenesis, employing advanced techniques in medicinal chemistry for drug discovery.

Analysis of her publication trends (2016-2021) reveals consistent innovation in heterocyclic derivatives—including naphthyridines, pyrimidines, and quinazolines—with demonstrated efficacy against HepG-2, PC-3, and HCT-116 cancer cell lines. Her work strategically integrates nanotechnology for enhanced drug delivery systems while maintaining strong focus on structure-activity relationships.

Dr. Awad's research has secured sponsorship from elite organizations including the National Research Foundation, Alexander von Humboldt-Stiftung, Science and Technology Development Fund, and Deutscher Akademischer Austauschdienst. These partnerships demonstrate her recognized scientific authority and facilitate high-impact collaborative projects in anticancer therapeutics development.